Group 1 - The core point of the article is that Zhenbao Island (603567) reported its A-share shareholder count as of January 20, 2026, which stands at 24,589 households [1]

Core Viewpoint - The company announced that its stock experienced an abnormal fluctuation, with a cumulative closing price increase of 20% over three consecutive trading days from January 19 to January 21, 2026 [1] Group 1 - The company conducted a self-examination and verified with its controlling shareholder, Huazhe Holdings, confirming that its production and operations are normal [1] - There are no undisclosed significant information or media reports that could have a substantial impact on the stock price [1] - During the period of abnormal fluctuation, the controlling shareholder, directors, and executives did not engage in any buying or selling of the company's stock [1] Group 2 - The company reminds investors to be cautious of trading risks [1]

在中医药现代化的时代浪潮下，传统中药工艺正借助科技力量实现迭代升级。近日，国家重点研发计划"中医药现代化"重点专项"12种中药发酵饮片关键 技术研究与产业化应用示范"项目启动会正式召开。作为该项目的核心参与企业，杭州市的桐君谷生物医药科技(浙江)有限公司(以下简称"桐君谷")凭借自 身技术与产业优势，助力中药发酵饮片产业突破发展瓶颈，加速现代化升级的步伐。 据悉，此次国家重点研发计划项目由河南中医药大学牵头统筹，汇聚了国内顶尖高校、科研院所及国内发酵中药龙头企业等多方优质资源，形成产学研用 深度融合的创新联合体。项目聚焦中药发酵饮片领域的核心技术瓶颈，以12种中药发酵饮片为研究对象，旨在突破关键工艺技术、构建科学质量控制体 系，最终实现产业化应用示范，助力中医药传承创新发展。 作为项目核心参与企业，桐君谷凭借深厚的产业积淀、领先的技术实力，成为推动项目落地见效的关键力量。据悉，桐君谷深耕中药发酵领域多年，不仅 自主研发了智慧发酵系统，成功培育12个发酵品种，更作为浙派发酵工艺的引领者，在中药发酵技术研发、产业化落地等方面积累了丰富经验。 在此次项目推进过程中，桐君谷将重点承担发酵中药智能装备研发、生产线集成与 ...

本次公司补血益母丸获批为首家中药二级保护品种，加强了公司产品的知识产权保护，将有利于提升公 司产品在产后恢复用药领域的市场竞争力，对公司的生产经营产生积极的影响。 格隆汇1月21日丨千金药业(600479.SH)公布，2026年1月20日，国家药品监督管理局网站发布了《中药 保护品种公告（第34号）》（2026年第11号），国家药品监督管理局批准公司的补血益母丸为首家中药 二级保护品种，补血益母丸为国基药品种、医保甲类品种、独家品种，被《国家基本药物临床应用指南 （中成药）2018年版》、《中成药临床应用指南（第二版妇科疾病分册）》、《中医妇科学（全国中医 药高等教育十四五规划教材）》等指南及教科书收录推荐。该产品适用于气血两虚兼血瘀证产后腹痛。 ...

Group 1 - The company expects a loss of 2.00 million to 4.00 million yuan in 2025, with a non-recurring loss of 15.00 million to 20.00 million yuan [1] - The primary reason for the performance change is that the newly expanded health consumer products and medical health business segments are still in the market cultivation phase, leading to high fixed cost allocation and a temporary impact on overall profits [1] - The estimated impact of non-recurring gains and losses on net profit during the reporting period is approximately 13.00 million to 16.00 million yuan [1]

格隆汇1月21日丨粤万年青(301111.SZ)公布，预计2025年亏损200.00万元–400.00万元，扣非亏损1,500.00 万元–2,000.00万元。本次业绩变动的主要原因系公司新拓展的健康消费品及医疗健康业务板块尚处于市 场培育期，相关业务收入尚未形成规模效应，导致固定成本分摊比例较高，从而对整体利润产生阶段性 影响。报告期内，公司预计非经常性损益对净利润的影响金额约为1,300-1,600万元。 ...

人民财讯1月21日电，千金药业（600479）1月21日公告，国家药品监督管理局批准公司的补血益母丸为 首家中药二级保护品种，该产品适用于气血两虚兼血瘀证产后腹痛。 ...

Market Overview - The Chinese traditional medicine sector experienced a decline of 0.39% on January 21, with Zhongsheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Stock Performance - Notable gainers in the traditional medicine sector included: - *ST Changyao: Closed at 0.64, up 20.75% with a trading volume of 519,700 shares and a turnover of 32.17 million yuan [1] - Tianmu Pharmaceutical: Closed at 22.29, up 8.47% with a trading volume of 128,100 shares and a turnover of 282 million yuan [1] - Wanbangde: Closed at 17.82, up 5.13% with a trading volume of 196,800 shares and a turnover of 34.2 million yuan [1] - Conversely, Zhongsheng Pharmaceutical saw a decline of 4.26%, closing at 21.12 with a trading volume of 685,100 shares and a turnover of 144.9 million yuan [2] Capital Flow - The traditional medicine sector experienced a net outflow of 281 million yuan from major funds, while retail investors saw a net inflow of 78.63 million yuan [2] - Major funds showed significant net inflows in stocks such as Yunnan Baiyao, which had a net inflow of 78.68 million yuan, and Wanbangde with a net inflow of 22.17 million yuan [3]

Core Viewpoint - The company expects a net profit loss attributable to shareholders of 2 to 4 million yuan in 2025, compared to a profit of 4.1627 million yuan in the same period last year [1] Group 1: Financial Performance - The primary reason for the performance change is that the newly expanded health consumer products and medical health business segments are still in the market cultivation phase, leading to high fixed cost allocation and a temporary impact on overall profits [1] - The company estimates that non-recurring gains and losses will impact net profit by approximately 13 to 16 million yuan during the reporting period [1]

Core Viewpoint - ST HuLuWa announced that its controlling shareholder, Hainan HuLuWa Investment Development Co., Ltd., will auction 23.9 million shares, representing 14.30% of its holdings and 5.97% of the company's total share capital, from February 27 to February 28, 2026 [1] Group 1 - The shares to be auctioned have been fully pledged and judicially frozen as of the announcement date [1] - If the auction is successful, the number of shares held by HuLuWa Investment will decrease to 143 million, reducing its holding percentage to 35.79%, but it will remain the controlling shareholder of the company [1]